Galazi, Myria, Rodriguez-Vida, Alejo, Ng, Tony, Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869 and Chowdhury, Simon 2014. Precision medicine for prostate cancer. Expert Review of Anticancer Therapy 14 (11) , pp. 1305-1315. 10.1586/14737140.2014.972948 |
Abstract
Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.
Item Type: | Article |
---|---|
Date Type: | Published Online |
Status: | Published |
Schools: | Medicine |
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
Publisher: | Taylor and Francis |
ISSN: | 1473-7140 |
Last Modified: | 31 Oct 2022 09:01 |
URI: | https://orca.cardiff.ac.uk/id/eprint/79563 |
Citation Data
Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |